Search

EHA-RHS-ROHS Hematology Tutorial 2021

EHA in collaboration with the National Hematological Society (RHS) and the Russian Onco-Hematology Society (ROHS) are closely monitoring the developments concerning the Coronavirus (COVID-19), as our priorities lie with the health and safety of our participants and partners.

Read more

Registration

Register here

The registration fee for the ESH-EBMT-EHA 3rd Translational Research Conference: Bone Marrow Failure and Leukaemia Predisposition Syndromes is:
– 600€ for fully trained
– 300€ for in-training *
– 300€ Allied Health Professionals
– 600€ for Corporate
*A proof will be requested to confirm your status.…

Read more

Hematology and oncology, pacemakers for EU HTA

EHA’s Martin Kaiser, right, addressing his fellow panelists. Left to right: Brian Cuffel (Bayer), Caroline Pothet (EMA), Roisin Adams (HTA CG), Bernhard Wörmann (DGHO) and Elisabeth de Vries (ESMO).

Read more

Clinical Practice Guidelines

EHA creates clinical practice Guidelines for diagnosis and treatment of hematologic diseases. This initiative started in 2019 with the establishment of the EHA Guidelines Committee and the definition of the EHA Methodology for Guidelines.

Read more

Non-EHA Funding Opportunities

Here you will find other interesting funding opportunities for European researchers in hematology. If you are interested in adding additional opportunities to this page, please contact research@ehaweb. org.

Read more

EHA-LSHBT Virtual Hematology Updates

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more